Innate Pharma prices private placement of new shares at EUR 1.7 each
IPHA•Closing, delivery and listing details
Closing is set for Aug. 18, 2026 at 8:30 a.m. CET, with investor cash due in euros by wire.
Shares are to be delivered in bearer form through Stifel as centralizing agent, with Société Générale Securities Services as registrar.
The new shares are expected to be listed on Euronext Paris on the closing date, subject to official issuance notice.
Private placement pricing and structure
Innate Pharma launched a capital increase without preferential rights, issuing new ordinary shares at EUR 1.7 each.
The U.S. tranche was structured as a private placement to Rule 144A QIBs, relying on the Securities Act Section 4(a)(2) exemption.
